{"nctId":"NCT01146873","briefTitle":"Treatment Options for Protease Inhibitor-exposed Children","startDateStruct":{"date":"2010-07"},"conditions":["HIV/AIDS","HIV Infections"],"count":300,"armGroups":[{"label":"Group 1: Lopinavir/ritonavir (LPV/r)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lopinavir/ritonavir (LPV/r)"]},{"label":"Group 2: Efavirenz (EFV)","type":"EXPERIMENTAL","interventionNames":["Drug: Efavirenz (EFV)"]},{"label":"Group D: Stavudine (D4T)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Stavudine (D4T)"]},{"label":"Group A: Abacavir (ABC)","type":"EXPERIMENTAL","interventionNames":["Drug: Abacavir (ABC)"]}],"interventions":[{"name":"Efavirenz (EFV)","otherNames":[]},{"name":"Lopinavir/ritonavir (LPV/r)","otherNames":[]},{"name":"Stavudine (D4T)","otherNames":[]},{"name":"Abacavir (ABC)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-infected child 3 to 5 years of age at time of screening for this trial if enrolled from outside or any age if enrolled from control arm of Neverest II.\n* Reliable history or documented exposure to NVP used as part of PMTCT\n* Initiated antiretroviral therapy with LPV/r at age less than 36 months\n* Receiving LPV/r-based ART for at least 12 months\n* At least one viral load measurement less than 50 copies/ml conducted as part of screening for the study\n* ALT measurement grade I or less (DAIDS Toxicity Tables 2004) (Appendix A). These may be repeated until ALTs normalize if necessary.\n\nExclusion criteria:\n\n* Prior treatment with any NNRTI drug as part of a therapeutic regimen\n* Substitution of other NRTI drugs (instead of 3TC and D4T which are the standard first line regimen) will be allowed.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Viral Rebound","description":"Probability of viral rebound defined as \\>=1 HIV RNA measurements \\>50 copies/ml using survival analysis by 48 weeks post-randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.284","spread":null},{"groupId":"OG001","value":"0.176","spread":null}]}]}]},{"type":"PRIMARY","title":"Viral Failure","description":"Probability of viral failure defined as \\>= 2 HIV RNA measurements \\>1000 copies/ml using survival analysis by 48 weeks post-randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.020","spread":null},{"groupId":"OG001","value":"0.027","spread":null}]}]}]},{"type":"SECONDARY","title":"CD4 Cell Percentage at 48 Weeks After Randomization","description":"CD4 Cell Percentage at 48 Weeks After Randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.7","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Elevated Total Cholesterol, Elevated LDL, Abnormal HDL, or Abnormal Triglycerides at 40 Weeks After Randomization","description":"Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.8","spread":null},{"groupId":"OG001","value":"10.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Highest Grade ALT After Randomization","description":"Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":148},"commonTop":[]}}}